BUZZ-Zura Bio falls after commencing stock offering

Reuters02-25 06:00

BUZZ-<a href="https://laohu8.com/S/ZURA">Zura Bio</a> falls after commencing stock offering

** Zura Bio's ZURA.O shares down 4.8% in extended trading to $6.37 after planned equity raise news

** Autoimmune and inflammatory diseases firm announces offering of shares and pre-funded warrants; deal size not disclosed

** It intends to use net offering proceeds for working capital, advance its pipeline, and general purposes, per the prospectus

** Co says its lead product candidate, tibulizumab, being evaluated in mid-stage studies for autoimmune conditions hidradenitis suppurativa and systemic sclerosis

** Leerink Partners, Piper Sandler and Cantor Fitzgerald joint bookrunners for offering

** Henderson, Nevada-headquartered co has ~73.7 mln shares outstanding, per LSEG data, for nearly $500 mln market cap

** ZURA shares on Tues closed up 2.5% at $6.69. Stock up ~28% YTD after more than doubling in 2025

** All 8 analysts are bullish including 4 "strong buy" ratings; median PT $15, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614725792?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 06:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614725792","market":"fut","top_or_hot":-1,"title":"BUZZ-Zura Bio falls after commencing stock offering","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/ZURA\">Zura Bio</a> falls after commencing stock offering</title></head><body><p>** Zura Bio's <span>ZURA.O</span> shares down 4.8% in extended trading to $6.37 after planned equity raise news</p><p>** Autoimmune and inflammatory diseases firm announces offering of shares and pre-funded warrants; deal size not disclosed</p><p>** It intends to use net offering proceeds for working capital, advance its pipeline, and general purposes, per the prospectus</p><p>** Co says its lead product candidate, tibulizumab, being evaluated in mid-stage studies for autoimmune conditions hidradenitis suppurativa and systemic sclerosis</p><p>** Leerink Partners, Piper Sandler and Cantor Fitzgerald joint bookrunners for offering</p><p>** Henderson, Nevada-headquartered co has ~73.7 mln shares outstanding, per LSEG data, for nearly $500 mln market cap</p><p>** ZURA shares on Tues closed up 2.5% at $6.69. Stock up ~28% YTD after more than doubling in 2025</p><p>** All 8 analysts are bullish including 4 \"strong buy\" ratings; median PT $15, per LSEG data</p><p>(Lance Tupper is a Reuters market analyst. The views expressed are his own)</p><p>((lance.tupper@tr.com 1-646-279-6380))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Zura Bio falls after commencing stock offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Zura Bio falls after commencing stock offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-25 06:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/ZURA\">Zura Bio</a> falls after commencing stock offering</title></head><body><p>** Zura Bio's <span>ZURA.O</span> shares down 4.8% in extended trading to $6.37 after planned equity raise news</p><p>** Autoimmune and inflammatory diseases firm announces offering of shares and pre-funded warrants; deal size not disclosed</p><p>** It intends to use net offering proceeds for working capital, advance its pipeline, and general purposes, per the prospectus</p><p>** Co says its lead product candidate, tibulizumab, being evaluated in mid-stage studies for autoimmune conditions hidradenitis suppurativa and systemic sclerosis</p><p>** Leerink Partners, Piper Sandler and Cantor Fitzgerald joint bookrunners for offering</p><p>** Henderson, Nevada-headquartered co has ~73.7 mln shares outstanding, per LSEG data, for nearly $500 mln market cap</p><p>** ZURA shares on Tues closed up 2.5% at $6.69. Stock up ~28% YTD after more than doubling in 2025</p><p>** All 8 analysts are bullish including 4 \"strong buy\" ratings; median PT $15, per LSEG data</p><p>(Lance Tupper is a Reuters market analyst. The views expressed are his own)</p><p>((lance.tupper@tr.com 1-646-279-6380))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL6N3ZK1I2:1","article_id":"2614725792","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614725792","pubTimestamp":1771970402,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Zura Bio falls after commencing stock offering** Zura Bio's ZURA.O shares down 4.8% in extended trading to $6.37 after planned equity raise news** Autoimmune and inflammatory diseases firm announces offering of shares and pre-funded warrants; deal size not disclosed** It intends to use net offering proceeds for working capital, advance its pipeline, and general purposes, per the prospectus** Co says its lead product candidate, tibulizumab, being evaluated in mid-stage studies for autoimmune conditions hidradenitis suppurativa and systemic sclerosis** Leerink Partners, Piper Sandler and Cantor Fitzgerald joint bookrunners for offering** Henderson, Nevada-headquartered co has ~73.7 mln shares outstanding, per LSEG data, for nearly $500 mln market cap** ZURA shares on Tues closed up 2.5% at $6.69. Stock up ~28% YTD after more than doubling in 2025** All 8 analysts are bullish including 4 \"strong buy\" ratings; median PT $15, per LSEG data","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","MNSH":"MNSN HLDGS INC.","BK4139":"生物科技","BK4127":"投资银行业与经纪业","ZURA":"Zura Bio","BK4207":"综合性银行","PIPR":"派杰投资"},"translate_title":"BUZZ-Zura Bio开始发行股票后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZURA":0.9,"PIPR":0.9,"MNSH":0.9},"content_text":"BUZZ-Zura Bio falls after commencing stock offering** Zura Bio's ZURA.O shares down 4.8% in extended trading to $6.37 after planned equity raise news** Autoimmune and inflammatory diseases firm announces offering of shares and pre-funded warrants; deal size not disclosed** It intends to use net offering proceeds for working capital, advance its pipeline, and general purposes, per the prospectus** Co says its lead product candidate, tibulizumab, being evaluated in mid-stage studies for autoimmune conditions hidradenitis suppurativa and systemic sclerosis** Leerink Partners, Piper Sandler and Cantor Fitzgerald joint bookrunners for offering** Henderson, Nevada-headquartered co has ~73.7 mln shares outstanding, per LSEG data, for nearly $500 mln market cap** ZURA shares on Tues closed up 2.5% at $6.69. Stock up ~28% YTD after more than doubling in 2025** All 8 analysts are bullish including 4 \"strong buy\" ratings; median PT $15, per LSEG data(Lance Tupper is a Reuters market analyst. The views expressed are his own)((lance.tupper@tr.com 1-646-279-6380))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614725792","isCrawlerRequest":true}